期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清CA125、HE4和YKL-40联合检测对卵巢恶性肿瘤的诊断价值 被引量：9

暂未订购
导出
摘要 目的探讨血清糖类抗原125(CA125)、人附睾蛋白4(HE4)和甲壳质酶蛋白40(YKL-40)联合检测对卵巢恶性肿瘤的早期诊断和预后的临床价值。方法血清标本取自40例卵巢恶性肿瘤、50例卵巢良性肿瘤。测定CA125、HE4和YKL-40,观察两组患者血清中三项指标的水平以及卵巢癌患者手术前后三项指标的水平变化。结果卵巢恶性肿瘤组血清CA125、HE4和YKL-40高于卵巢良性肿瘤组,其差异有显著性(P<0.01),经过理想肿瘤减灭术的卵巢癌患者术后1周血清中上述3项指标水平明显低于手术前水平(P<0.001)。结论血清CA125、HF4和YKL-40联合检测有助于提高卵巢恶性肿瘤的早期诊断和预后分析。
作者 黄静
机构地区 山东医学高等专科学校附属医院妇产科
出处 《中国医刊》 CAS 2014年第2期69-70,共2页 Chinese Journal of Medicine
关键词 卵巢癌 糖类抗原125 人附睾蛋白4 甲壳质酶蛋白40
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Yip P,Chen TH,Seshaiah P,et al. Comprehensive serum profiling for the diseovery of epithelial ovarian cancer biomarkers [ J ]. PLoS One,2011,6 ( 12 ) :e29533.
  • 2Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees[J]. Future Oncol,2012,8( 1 ) :55-71.
  • 3郑伟达,郑东海,郑伟鸿.卵巢癌中医治疗体会[J].世界中医药,2011,6(4):316-317. 被引量：8
  • 4Thakur A, Mishra V, Jain SK. Feed forward artificial neural net- work: tool for early detection of ovarian cancer [ J ]. Sci Pharm, 2011,79 (3) :493-505.
  • 5Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a sus- picious cystic ovarian mass [ J ]. J Gynecol Oncol, 2011 , 22 ( 4 ) : 244-252.
  • 6Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diag- nostic test in ovarian cancer: prospective validation of the Risk of O- varian Malignancy Algorithm [ J ]. Br J Cancer, 2011 , 104 ( 5 ) : 863 -870.
  • 7Li F,Tie R,Chang K,et al. Does risk for ovarian malignancy algo- rithm excel human epididymis protein 4 and CA125 in predicting ep- ithelial ovarian cancer: a meta-analysis [ J ]. BMC Cancer, 2012, 12:258.
  • 8Kalantri Y,Naik G,Joshi SP,et al. Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions[ Jl. Indi- an J Med Res,2007,125:25-30.
  • 9Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer[ J]. J Ovarian Res,2012,5(1):20.
  • 10谢服役,孙琦,吴巧萍.血清HE4和CA125联合预测卵巢肿瘤的风险[J].医学研究杂志,2012,41(7):150-153. 被引量：5

二级参考文献24

  • 1杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量：17
  • 2Walsh JM, Dolan NC, Charney P, et al. Update in womenE's health [J]. Ann Int Med, 2000, 133(10):808-814.
  • 3MenonU, Jacobs IJ. Recent developments in ovarian cancer screening [J]. Curr Opin Obstet Gynaecol, 2000, 12(1) : 39-42.
  • 4Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40 [J]. J Clin Oncl, 2004,22(16) : 3330-3339.
  • 5Johansen JS, Drivsholm L, Price PA, et al. High serum YKL- 40 level in patients with small cell lung cancer is related to early death [J]. Lung Cancer, 2004,46(3) :333-340.
  • 6Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer [J]. Gynecol Oncol, 2007,104(2):435-442.
  • 7Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis [J]. Oncogene, 2006,25(8) : 1242-1250.
  • 8Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer [J]. Dan Med Bull, 2006,53(2):172-209.
  • 9Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? [J]. Cancer Epidemiol Biomarkers Prov, 2006,15(2) : 194-202.
  • 10Dehn H, Hogdall E V, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer [J]. Acta Obstec Gynecol Stand, 2003,82(3) : 287-293.

共引文献22

同被引文献110

  • 1Kirchhoff C, Habben I, Ivell R. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular pro- teinase inhibitors [ J ]. Biology of Reproduction, 1991,45 ( 2 ) : 350 - 357.
  • 2Sehummer M, Bumgarner RE, Nelson PS, et al. Comparative hy- bridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas[ J]. Gene, 1999,238 (2) :375 -385.
  • 3Ramus SJ, Kartsonaki C, Gayther SA, et al. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers[J]. J Natl Cancer Inst,2011,103 (2):105-116.
  • 4Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer [J]. Int J Cardiovasc Imaging, 2011,43(11):1104-1107.
  • 5Stany MP, Maxwell GL, Rose GS, et al. Clinical decision making using ovarian cancer risk assessment [J]. A JR Am J Roentgenol, 2010,194(2):337-342.
  • 6Tapia V, Gabler F, Munoz M, et al. Tyrosine kinase A receptor (tr-kA):a potential marker in epithelial ovarian cancer [J]. Gynecol Oncol, 2011, 121(1):13-23.
  • 7Bilici A,Ustaalioglu BB,Seker M.Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer:Is there an impact of FDG PET/CT on patient management[J].European Journal of Nuclear Medicine and Molecular Imaging,2010,37(5):1259-1269.
  • 8DeToledo MCS,Sarian,LO,Sallum,LF.et al.Analysis of the contribution of immunologically-detectable HER2,steroid receptors and of the "triple-negative" tumor sta- tus to disease-free and overall survival of women with epithelial ovarian cancei[J].Acta Histochemica:Zeitschrift fur Histologische Topochemie,2014,116(3);440-447.
  • 9邵 婷,陈秀玮.卵巢癌的病因假说及危险因素和流行病学研究进展[J/CD].中华临床医师杂志(电子版),2013,7(19):8894-8897.
  • 10Ortiz - Munoz B, Aznar - Oroval E, Garcia Garcia A,et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian caneer [J]. Turnout biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014,35 ( 7 ) :7249 - 7258.

二级引证文献37

中国医刊
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部